Skip to main content

InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports Data from Preclinical Studies Indicating Proprietary Drug Candidate Reduces Agitation in Alzheimer’s Mouse Model

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting additional positive results from preclinical studies investigating its newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer’s disease. The company had already shared study results indicating that TGR-63 shows potential to alleviate plaque burden in Alzheimer’s cell lines and animal models. New results exhibit potential recovery of behavioral functions in an animal model of Alzheimer’s, which could indicate that TGR-63 could be used as a treatment for anxiety in human Alzheimer’s. The company observed that TGR-63 is a patent-pending molecule designed to disrupt the structure of the amyloid beta (“Aβ”) peptide, one of the key hallmarks of Alzheimer’s. “While we continue to progress our phase 2b trial of IGC-AD1 as a treatment for agitation in dementia due to Alzheimer’s, we are excited by the preclinical results of TGR-63, in particular the profound impact of the drug on plaques and on reducing anxiety in a transgenic Alzheimer’s mouse model,” said IGC Pharma CEO Ram Mukunda in the press release. “In line with IGC Pharma’s artificial intelligence and machine learning (‘AI/ML’) initiatives, we plan to leverage cutting-edge AI/ML tools for studying TGR-63’s toxicology and protein interactions. By harnessing the power of AI/ML, we expect to accelerate the journey of TGR-63 from preclinical to patient care. We continue progressing IGC-AD1 and TGR-63 enthusiastically and anticipate clinical milestone updates throughout 2024 from our strengthened AD pipeline.”

To view the full press release, visit

About IGC Pharma

IGC Pharma is pursuing innovative solutions to fight Alzheimer’s disease and related challenges. The company’s portfolio comprises five assets, all with a singular mission: to transform the landscape of Alzheimer’s treatment. IGC-AD1 and LMP target neuroinflammation, Aβ plaques and neurofibrillary tangles. IGC-AD1 is currently in a phase 2b clinical trial for agitation in dementia due to Alzheimer’s. TGR-63 targets Aβ plaque to disrupt the progression of Alzheimer’s disease. IGC-M3 targets the inhibition of Aβ plaque aggregation with the potential to create a profound impact on early-stage Alzheimer’s. IGC-1C targets tau and neurofibrillary tangles as a forward-thinking approach to Alzheimer’s therapy. In parallel, IGC Pharma is at the forefront of generative AI development, with projects including clinical trials, early detection of Alzheimer’s and drug interactions with cannabinoids. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:

Los Angeles, CA
310.299.1717 Office

InvestorWire is powered by IBN

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.